Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,001 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Discrete Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

NCT00985673
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

NCT05722262
View directory record Official record
Conditions
Healthy
Interventions
K-001, K-877-ER, CSG452
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

NCT03650803
View directory record Official record
Conditions
Breast Cancer
Interventions
3D MR Fingerprinting scan
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 30, 2026, 6:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Idiopathic Edema

NCT01681927
View directory record Official record
Conditions
Idiopathic Edema Nocturia
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

NCT00005988
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloma
Interventions
cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, in vitro-treated bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

NCT03376997
View directory record Official record
Conditions
Healthy Participants
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Not applicable Interventional

Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index

NCT03092310
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Artificial Pancreas Device
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SATISFY (geleSis100 Effects on AppeTIte Sensations, Feeding Behavior and Dietary energY)

NCT04257123
View directory record Official record
Conditions
Appetitive Behavior
Interventions
Gelesis100, Placebo
Device · Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 30, 2026, 6:11 PM EDT
Withdrawn Not applicable Interventional

Partial Breast Irradiation in a Low-risk Population Screened With MRI

NCT01255553
View directory record Official record
Conditions
Breast Cancer
Interventions
Partial Breast Irradiation
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
40 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

NCT06064929
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Felzartamab
Drug
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

NCT02993731
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
Napabucasin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
99
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

NCT04696393
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Mitapivat tablet
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

BREATHE 2 Clinic Stop-Smoking Treatment Outreach Study

NCT05683821
View directory record Official record
Conditions
Quitting Smoking, Smoking Cessation, Smoking, Cigarette
Interventions
Text message smoking treatment, Nicotine replacement therapy sampling, Wisconsin Tobacco QuitLine Referral, Referral to Primary Care Provider, BREATHE 2 Cessation Study, Additional modalities to learn about and request treatment
Behavioral · Drug · Combination Product
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12,376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 6:11 PM EDT
Withdrawn Phase 1 Interventional

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

NCT04361058
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic Syndrome Acute Myeloid Leukemia
Interventions
Nivolumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 30, 2026, 6:11 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Experiment 2: One Target in Many Situations

NCT06934148
View directory record Official record
Conditions
Vision, Healthy, Attention
Interventions
Blocked Trials, Mixed trials
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies

NCT01846143
View directory record Official record
Conditions
Melanoma
Interventions
pBCAR3-phosphopeptide, pIRS2-phosphopeptide, 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

NCT06219915
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1, Placebo 2
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 30, 2026, 6:11 PM EDT
Active, not recruiting Early Phase 1 Interventional

Naltrexone Neuroimaging in Teens With Eating Disorders

NCT05509257
View directory record Official record
Conditions
Eating Disorders, Binge Eating, Purging (Eating Disorders), Bulimia Nervosa, Anorexia Nervosa, Atypical
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
13 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Brain Imaging of Intranasal Oxytocin Treatment in Autism

NCT01945957
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Results available

Characteristics of Glargine in Type 2 Diabetics

NCT00574912
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 30, 2026, 6:11 PM EDT
Terminated Not applicable Interventional

External Ventricular Drain Placement Stealth Study

NCT03696043
View directory record Official record
Conditions
External Ventricular Drain, Intracranial Pressure
Interventions
Axium Steatlh Image Guidance, EVD placement
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 88 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Nitrous Oxide as Treatment for Major Depression - a Pilot Study

NCT02139540
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Nitrous Oxide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 30, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain

NCT02372591
View directory record Official record
Conditions
Opioid-Related Disorders, Chronic Pain
Interventions
Buprenorphine, Hydromorphone, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 30, 2026, 6:11 PM EDT
Enrolling by invitation Phase 4 Interventional

Vevye + Flarex Combination Therapy for Dry Eye

NCT07553455
View directory record Official record
Conditions
Dry Eye
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution), Flarex
Drug
Lead sponsor
Canyon City Eyecare
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 6:11 PM EDT